Handelen Arcus Biosciences, Inc. - RCUS CFD

Handelsvoorwaarden

• Type: CFD
• Spread: 0.26
• Renteaanpassing voor het nachtelijk aanhouden van een long positie: -0.02229%
• Renteaanpassing voor het nachtelijk aanhouden van een short positie ~: 0.00007%
• Renteaanpassing voor het nachtelijk aanhouden: 22:00 (UTC)
• Valuta: USD
• Min. verhandelde hoeveelheid: 1
• Marge: 20.00%
• Effectenbeurs: United States of America
• Handelscommissie: 0%
• Premie voor gegarandeerde stop-loss: 1%

Belangrijkste statistieken

• Vorige slotkoers: 21.11
• Openingskoers: 21.13
• 1-Jaarlijkse Verandering: 45.42%
• Dagelijks bereik: 20.86 - 22.42

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company''s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.; and co-development and co-commercialization partnership with Gilead Sciences, Inc. for the development of cancer immunotherapies. The company was founded in 2015 and is based in Hayward, California.